Treatment of transthyretin (ATTR) amyloidosis in observational study setting
Pre-clinicalRecruiting 2 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Transthyretin Amyloidosis
Conditions
Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN, ATTR, ATTR-Mixed, hATTR
Trial Timeline
Jun 25, 2024 → Dec 29, 2031
NCT ID
NCT06465810About Treatment of transthyretin (ATTR) amyloidosis in observational study setting
Treatment of transthyretin (ATTR) amyloidosis in observational study setting is a pre-clinical stage product being developed by AstraZeneca for Transthyretin Amyloidosis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06465810. Target conditions include Transthyretin Amyloidosis, ATTR-CM, ATTRv-PN.
What happened to similar drugs?
3 of 19 similar drugs in Transthyretin Amyloidosis were approved
Approved (3) Terminated (0) Active (16)
Hype Score Breakdown
Clinical
3
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06465810 | Pre-clinical | Recruiting |
Competing Products
20 competing products in Transthyretin Amyloidosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Eplontersen Solution for Injection | AstraZeneca | Phase 1 | 29 |
| Eplontersen + Placebo | AstraZeneca | Phase 3 | 44 |
| Eplontersen | AstraZeneca | Phase 3 | 47 |
| Eplontersen + Placebo | AstraZeneca | Phase 3 | 44 |
| NNC6019-0001 + Placebo (NNC6019-0001) | Novo Nordisk | Phase 3 | 47 |
| NNC6019-0001 | Novo Nordisk | Phase 2 | 39 |
| NNC6019-0001 + Placebo (NNC6019-0001) | Novo Nordisk | Phase 2 | 35 |
| Coramitug | Novo Nordisk | Phase 1 | 36 |
| Tafamidis | Pfizer | Pre-clinical | 26 |
| Tafamidis | Pfizer | Pre-clinical | 30 |
| tafamidis meglumine | Pfizer | Approved | 43 |
| Fx-1006A | Pfizer | Phase 2 | 35 |
| Tafamidis | Pfizer | Phase 3 | 40 |
| Tafamidis 61 milligrams | Pfizer | Pre-clinical | 26 |
| Treatment for TTR amyloidosis + Treatment for TTR amyloidosis | Pfizer | Pre-clinical | 26 |
| Vyndaqel | Pfizer | Pre-clinical | 26 |
| tafamidis | Pfizer | Phase 3 | 40 |
| Tafamidis | Pfizer | Approved | 43 |
| Tafamidis | Pfizer | Pre-clinical | 26 |
| Vyndamax (tafamidis 61mg) | Pfizer | Pre-clinical | 30 |